Clinically Proven Dose-Dependency: Proprietary ProbioticConsortia Modulate Gut Microbiota and Suppress Obesity-Linked Inflammation inHuman Trial

Title:  

Clinically Proven Dose-Dependency: Proprietary ProbioticConsortia Modulate Gut Microbiota and Suppress Obesity-Linked Inflammation inHuman Trial  

Blue Eyes Biotech Co., Ltd. reveals groundbreakingdose-response evidence from a 16-week RCT demonstrating our precision probioticformulations significantly reduce systemic inflammation in obese populations.Using triple-encapsulated strains (Bifidobacterium/Lactobacillus genera), weestablished:  

✅ Strain-Specific Thresholds: 5×10¹⁰ CFU/day achieved 32.7% IL-6 reduction (p<0.01) vs. sub-effective10⁹ CFU  

✅ Microbiota Restoration: +47% Akkermansiaabundance at optimal dosing (qPCR/SHIME® validation)  

✅ Endotoxin Control: 39.2% lower serum LPScorrelated with TLR4/NF-κB downregulation

Mechanistic Advantages for Developers:  

1. Triple-Target Action:  

   -Barrier integrity (ZO-1↑)  

   -Butyrate production (+3.1x vs. baseline)

   -Macrophage polarization (M1→M2 shift)  

2. Synbiotic Potentiation:  

   -Prebiotic-matched blends (FOS/XOS) enhance colonization resistance  

   -Acid/bile-resistant DRcaps™ technology (>90% gastric survival)  

Application-Ready Solutions:  

•WeightManagement Supplements: Clinically validated inflammation claims  

•FunctionalFoods: Stable powder blends for beverages/confectionery  

•PharmaceuticalAdjuvants: Anti-inflammatory biologics co-therapy  

Technical Superiority:  

- Strain banking (≥10⁴⁵ CFUmaster stock)  

- Viability guarantee: 24-month stabilityat 25°C/60% RH  

- Customizable formats: CFU tiers (10⁹-10¹²/g), enteric/spray-dried

Full-Service Partnership Includes:  

✓Dose-Response Study Design: Biomarkerendpoint optimization  

✓IP Protection: Non-infringing strainselection  

✓Scale Flexibility: R&D kits to20-ton annual capacity (cGMP)  

Access Clinical Data Sheets & StrainDossiers:  

[email protected]  

Explore Probiotic Innovations:www.blueeyes-bio.com